Analystreport

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its price target lowered by analysts at Piper Sandler from $45.00 to $41.00. They now have an "overweight" rating on the stock.

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com